|1.||Youdim, Moussa B H: 19 articles (03/2013 - 03/2002)|
|2.||Amit, Tamar: 14 articles (04/2012 - 10/2002)|
|3.||Bar-Am, Orit: 13 articles (04/2012 - 10/2002)|
|4.||Weinreb, Orly: 9 articles (04/2012 - 10/2006)|
|5.||Weinstock, Marta: 8 articles (03/2013 - 03/2002)|
|6.||Yogev-Falach, Merav: 5 articles (01/2008 - 10/2002)|
|7.||Weinstock, M: 5 articles (08/2007 - 01/2000)|
|8.||Bejar, Corina: 4 articles (03/2013 - 03/2002)|
|9.||Sagi, Yotam: 4 articles (09/2008 - 06/2003)|
|10.||Luques, Lisandro: 3 articles (03/2013 - 06/2011)|
|1.||Neurodegenerative Diseases (Neurodegenerative Disease)
09/25/2008 - "These findings indicate that in addition to its multiple neuroprotective characteristics, ladostigil also possesses antioxidant properties, which might be beneficial for the treatment of oxidative stress (OS) in aging and age-associated neurodegenerative diseases."
12/01/2007 - "These studies indicate that the induction of NTFs by rasagiline and ladostigil might suppress apoptosis and induce neurorescue in neurodegenerative disorders and may support the drugs' possible disease-modifying mechanism of action."
02/01/2009 - "In addition to its unique combination of ChE and MAO enzyme inhibition, these results indicate that ladostigil displays neuroprotective activity against oxidative stress-induced cell apoptosis, which might be valuable for aging and age-associated neurodegenerative diseases."
10/01/2007 - "Our findings suggest that both metabolites may contribute to the overall neuroprotective activity of their respective parent compounds, further implicating rasagiline and ladostigil as potentially valuable drugs for treatment of a wide variety of neurodegenerative disorders of aging."
12/01/2006 - "Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil."
01/01/2008 - "Preclinical studies show that ladostigil has antidepressant and anti-AD activities and the clinical development is planned for these dementias. "
03/01/2013 - "The unique multiple actions of ladostigil and M30 make the potentially useful drugs for the treatment of dementia with Parkinsonian-like symptoms and depression."
06/01/2003 - "These unique multiple actions of TV-3326 make it a potentially useful drug for the treatment of dementia with Parkinsonian-like symptoms and depression."
03/01/2002 - "Together with its neuroprotective properties, this action could make TV3326 a potentially valuable drug for the treatment of dementia in patients with depression."
10/01/2005 - "Our results suggest that potentiation of both aminergic and cholinergic transmission systems by ladostigil contributes equally to motor behavior performance, which is substantially impaired in comorbidity of dementia with Parkinsonism including dementia with Lewy bodies (DLB)."
|3.||Memory Disorders (Memory Loss)
03/01/2013 - "Ladostigil (1 mg/kg/day) prevents the development of age-related memory deficits by a combination of immunomodulatory and antioxidant effects. "
06/01/2011 - "Ladostigil prevents age-related glial activation and spatial memory deficits in rats."
03/01/2013 - "However, at 20 months, when NOR was impaired and brain acetylcholine levels are 40 % below normal, ladostigil (8.5 mg/kg) reversed the memory deficit. "
03/01/2007 - "Daily oral administrations of ladostigil (1mg/kg) for 1 week, before and after STZ prevented the glial changes, increase in nitrotyrosine immunoreactivity and memory deficits. "
03/01/2007 - "Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats."
02/01/2009 - "The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats."
09/25/2008 - "In the present study, we demonstrate that ladostigil (1 microM) increased cell viability, associated with the increase of catalase activity and decrease of intracellular reactive oxygen species (ROS) production in human SH-SY5Y neuroblastoma cells exposed to (hydrogen peroxide) H(2)O(2). "
02/01/2009 - "In the present study, we demonstrate that ladostigil (10(-6)-10 muM) dose-dependently increased cell viability, associated with increased activity of catalase and glutathione reductase and decrease of intracellular reactive oxygen species production in a cytotoxic model of human SH-SY5Y neuroblastoma cells exposed to hydrogen peroxide (H(2)O(2)). "
12/01/2001 - "Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus. "
02/01/2009 - "In addition, ladostigil significantly upregulated mRNA levels of several antioxidant enzymes (catalase, NAD(P)H quinone oxidoreductase 1 and peroxiredoxin 1) in both H(2)O(2)-treated SH-SY5Y cells, as well as in the high-density human SK-N-SH neuroblastoma cultured apoptotic models. "
|5.||Basal Ganglia Diseases (Basal Ganglia Disease)
01/01/2011 - "Ladostigil combines neuroprotective effects with monoamine oxidase-A and -B and cholinesterase inhibitory activities in a single molecule, presently in a Phase IIb clinical trial and intended for the treatment of Alzheimer's disease, and dementia comorbid with extrapyramidal disorders and depression. "
04/01/2012 - "Ladostigil [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] is a dual acetylcholine-butyrylcholineesterase and brain selective monoamine oxidase (MAO)-A and -B inhibitor in vivo (with little or no MAO inhibitory effect in the liver and small intestine), intended for the treatment of dementia co-morbid with extrapyramidal disorders and depression (presently in a Phase IIb clinical study). "
|1.||Reactive Oxygen Species (Oxygen Radicals)
|2.||Hydrogen Peroxide (Hydroperoxide)
|5.||Monoamine Oxidase (MAO)
|9.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)